Status:
COMPLETED
Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases
Lead Sponsor:
Pfizer
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will evaluate the safety, tolerability and efficacy of SU011248 in patients with non-small cell lung cancer with brain metastases.
Eligibility Criteria
Inclusion
- Patients with radiologically proven brain metastases secondary to non-small cell lung cancer
- Received previous whole brain radiation therapy and none, 1 or 2 prior systemic therapy for the treatment of advanced/metastatic non-small cell lung cancer
Exclusion
- Patients with brainstem lesions, spinal cord compression. carcinomatous meningitis, or leptomeningeal disease.
- Brain metastases \>4 cm in any linear direction
- Intracranial or intratumoral hemorrhage
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT00372775
Start Date
March 1 2007
End Date
December 1 2009
Last Update
February 24 2011
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Norwalk, Connecticut, United States, 06856
2
Pfizer Investigational Site
Cocoa Beach, Florida, United States, 32931
3
Pfizer Investigational Site
Merritt Island, Florida, United States, 32952
4
Pfizer Investigational Site
Titusville, Florida, United States, 32796